Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 2:64:e3.
doi: 10.1590/S1678-9946202264003. eCollection 2022.

SARS-CoV-2 testing among patients and healthcare professionals in an HIV outpatient clinic in Brazil

Affiliations

SARS-CoV-2 testing among patients and healthcare professionals in an HIV outpatient clinic in Brazil

Elaine Monteiro Matsuda et al. Rev Inst Med Trop Sao Paulo. .

Abstract

The COVID-19 pandemic in Brazil has been marked by high infection and death rates. The immune response generated by current vaccination might be influenced by previous natural infection, and baseline estimates may help in the evaluation of vaccine-induced serological response. We evaluated previous SARS-CoV-2 testing (RT-PCR), and performed rapid diagnostic tests (RDT) and high throughput electrochemiluminescence immunoassay (ECLIA) before vaccination among people living with HIV (PLWH), users of antiretroviral prophylaxis (PrEP/PEP), and healthcare professionals in an HIV outpatient clinic (HCP-HC). RDT was positive in 25.7% (95% CI: 19-33%) overall, 31.3% (95% CI : 18-45%) among PLWH, 23.7% (95% CI : 14-34%) in PrEP/PEP users and 21.4% (95% CI : 05-28%) in HCP-HC (p=0.548). Diagnostic RT-PCR testing was very limited, even for symptomatic individuals, and whereas all HCP-HC had one test perfomed, only 35% of the patients (PREP/PEP/PLWH) were tested (p<0.0001). Adequate monitoring of post-vaccination humoral response and breakthrough infections including those in asymptomatic cases are warranted, especially in immunologically compromised individuals.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTERESTS

The authors declare that there are no conflicts of interest.

References

    1. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJ, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5:1598–1607. - PMC - PubMed
    1. World Health Organization Global: Brazil. [cited 2021 Nov 8]. https://covid19.who.int/region/amro/country/br/
    1. Jangra S, Landers JJ, Rathnasinghe R, O’Konek JJ, Janczak KW, Cascalho M, et al. A combination adjuvant for the induction of potent antiviral immune responses for a recombinant SARS-CoV-2 protein vaccine. 729189Front Immunol. 2021;12 - PMC - PubMed
    1. Wang Y, Feng R, Xu J, Shi L, Feng H, Yang H. An updated meta-analysis on the association between HIV infection and COVID-19 mortality. AIDS. 2021;35:1875–1878. - PubMed
    1. Centers for Disease Control and Prevention Symptoms of COVID-19. [cited 2021 Nov 8]. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html